Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

Osteoporosis International

Volumn 24, Issue 1, 2013, Pages 293-299

  McClung, M R ^a   Zanchetta, J R ^b   Racewicz, A ^c   Roux, C ^d   Benhamou, C L ^e   Man, Z ^f   Eusebio, R A ^g   Beary, J F ^g   Burgio, D E ^g   Matzkin, E ^h   Boonen, S ⁱ   Delmas, P ^j  

^a OREGON OSTEOPOROSIS CENTER   (United States)

^b Instituto de Investigaciones Metabolicas   (Argentina)

^c Centrum Medyczne Specjalistyczny Gabinet Lekarski Bialystok   (Poland)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSERM   (France)

^f Centro TIEMPO   (Argentina)

^g PROCTER AND GAMBLE COMPANY   (United States)

^h SANOFI   (France)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

^j UNIVERSITÉ DE LYON   (France)

more..

Author keywords

Bone mineral density; Fracture risk; Monthly; Osteoporosis; Risedronate

Indexed keywords

CALCIUM; RISEDRONIC ACID; VITAMIN D;

ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE PAIN; BONE TURNOVER; BRONCHITIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMUR NECK; HEART ATRIUM FIBRILLATION; HUMAN; INFLUENZA; LUMBAR SPINE; MAJOR CLINICAL STUDY; MUSCULOSKELETAL PAIN; MYALGIA; NECK PAIN; NEOPLASM; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RHINOPHARYNGITIS; SPINE FRACTURE; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TREATMENT OUTCOME;

EID: 84872333047     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2056-0     Document Type: Article

References (10)

1. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
2. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83-91
3. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
4. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA et al (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111
5. Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R et al (2008) Monthly dosing of 75-mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 19:1039-1045
6. Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL et al (2008) Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36-42
7. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148
8. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D et al (2000) Therapeutic equivalence of alendronate 70-mg once-weekly and alendronate 10-mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1-12
9. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315-1322
10. EMEA (2008) Evaluation of new medicinal products in the treatment of primary osteoporosis [homepage on the Internet]. European Medicines Agency, Committee for Medicinal Products for Human Use, London, England; c1995-2010 [updated 2008 Nov 25; cited 2010 Jan 25]. At: http://www.ema.europa.eu/pdfs/ human/ewp/55295enfin.pdf